Related Experiment Videos
Multiple endocrine neoplasia type 1 (MEN1) in Austria
Andreas Weinhäusel1, Klaus Kaserer, Heinrich Vierhapper
1Children's Cancer Research Institute, St Anna Children's Hospital, Vienna, Austria.
Wiener Klinische Wochenschrift
|July 2, 2002
Summary
Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic syndrome. Molecular screening accurately identifies mutation carriers, enabling early tumor detection and personalized management for affected families.
Area of Science:
- Endocrinology
- Genetics
- Oncology
Background:
- Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant inherited cancer predisposition syndrome.
- Caused by inactivating germ-line mutations in the MEN1 tumor suppressor gene.
- Individuals are prone to developing tumors in parathyroid, pituitary, and enteropancreatic endocrine tissues.
Purpose of the Study:
- To establish a molecular genetic screening program in Austria to differentiate heritable from non-heritable endocrine tumor forms.
- To identify MEN1 germ-line mutations in patients with endocrine tumors and their relatives.
Main Methods:
- Sequencing of coding exons 2 to 10 of the MEN1 gene.
- Study included 42 individuals from seven families with suspected MEN1 and 22 patients with sporadic endocrine tumors.
- Screening extended to first-degree relatives upon identification of a MEN1 mutation.
Main Results:
- Germ-line MEN1 mutations were found in 4 of 7 suspected families and 3 of 22 (13.6%) patients with sporadic tumors.
- Identified mutations were present in three first-degree relatives, including one asymptomatic child.
- Distinguished between genetically predisposed individuals and those without the mutation.
Conclusions:
- Molecular genetic screening significantly impacts the diagnosis and clinical management of MEN1.
- Allows for close monitoring and early treatment of symptomatic and asymptomatic mutation carriers.
- Facilitates accurate genetic counseling and reduces unnecessary surveillance for unaffected relatives.